Eli Lilly is set to offer a cheaper alternative to its most popular insulin, Humalog, and while the generic will carry a 50 percent discount, the drugmaker has received some criticism from policymakers for the move.
Democratic Sen. Ron Wyden dubbed the move “PR acrobatics,” according to STAT, and added that the Senate Finance Committee will launch an investigation into the drugmaker’s decision to “offer a generic version of a several-decade-old drug.”
“Looking fwd to getting THOROUGH responses from insulin cos to letters we sent,” Sen. Chuck Grassley tweeted, referencing letters he and Wyden sent to Lilly, Sanofi and Novo Nordisk demanding information regarding insulin prices.
Rep. Lloyd Doggett, a Democrat, claimed Lilly was attempting to bolster its “market dominance, maintain consumer brand loyalty, and … promote the brand over the generic.”
To read more on STAT, click here.